Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. - Wikidata - wikimedia - TriplyDB

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

http://www.wikidata.org/entity/Q36851454

about

Orthostatic hypotension and incident heart failure in community-dwelling older adults.Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure Core Measures for Congestive Heart Failure in a Tertiary Care Setting in Pakistan Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure Renin-angiotensin system blocking drugs.Characteristics, Management, and Outcomes of Acute Heart Failure in the Emergency Department: A Multicenter Registry Study with 1-year Follow-up in a Chinese Cohort in Beijing.Targets for Heart Failure With Preserved Ejection Fraction.Use and Interpretation of Propensity Scores in Aging Research: A Guide for Clinical Researchers.Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators.Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Association is not causation: treatment effects cannot be estimated from observational data in heart failure

P2860

Q33684590-575D95EC-1FA2-40B5-BE42-6BCB1DB42247 Q37135514-1ABCB2AA-1804-455B-AF69-1E1100B119F2 Q37242299-24403BD6-4707-4F05-BD8E-8956155018BF Q37283337-ACE6E797-0416-4B41-9FC1-EF7769B92BC3 Q37292234-C02CDC23-1D2E-46ED-9BBB-C932E1E4B986 Q37594550-40FB888F-3800-4D6E-9CF4-FF732C831ECB Q38137851-9C6716AD-8F91-46B4-AF57-0FB4EDF94DA5 Q38641541-25EF7371-0CA1-416C-BB93-B7BC82315B45 Q38688194-F1E24660-0ACA-442A-BECE-DED39EFCAC91 Q38934403-56F64B1D-6A52-4635-BEAA-D3E7170C6C41 Q39432098-41C29C68-AAA4-42FF-A6C8-C69FE38E5936 Q40202565-65EAA0FB-E923-4C39-A98D-933802036DB2 Q43063161-C7695677-7F5C-4B18-B040-2453CD9E991B Q46874079-51E12263-51F5-4473-8DA6-C344B1FFD0AC Q58804164-BE65049C-84A4-46CE-B6B2-639D406BA0EF

P2860

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

http://www.wikidata.org/entity/Q36851454

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Angiotensin-converting enzyme ...... d preserved ejection fraction.

@en

type

label

Angiotensin-converting enzyme ...... d preserved ejection fraction.

@en

prefLabel

Angiotensin-converting enzyme ...... d preserved ejection fraction.

@en

P1433

Q36851454-18E946FE-0DA7-41A2-8377-A05D37D264B8

P1476

Q36851454-0951BD37-BD82-4336-964D-5117DCCAEC08

P2093

Q36851454-403A71E8-40C9-4227-9C4E-F10548D4C355

Q36851454-5160FD3A-9543-4C64-B39E-2CD599101AB5

Q36851454-70974BEC-EB84-454E-9F91-637CB0ED615C

Q36851454-9418DF4D-43D7-41A3-980D-529DD65E41D9

Q36851454-97F3EE3B-E37E-4BA1-A279-A6B27B6F47F7

Q36851454-E00B90FC-8312-4109-9390-7532C300B5AF

Q36851454-EDD31BCC-85E7-44CF-AF41-E970959DBAA0

P2860

Q36851454-03654077-E6EB-4F22-B8A3-19745AF6FE5A

Q36851454-088BAA85-96CA-401D-BADE-5D383D1C77BC

Q36851454-0B22A334-233D-4CCD-A8A7-8CC36E01C97B

Q36851454-0E8387EF-6ED4-43A6-9AF3-95E7085219B2

Q36851454-10B9E361-B15F-469D-9468-5D534B0918E4

Q36851454-16872B02-3BCE-4E67-9D03-07138C37555A

Q36851454-173864CE-3429-4019-8385-617326EBEAB9

Q36851454-2027A5B3-FF3E-45FA-8B0F-BA33A36088EC

Q36851454-268F19B0-A1E8-4D6E-9F6B-47295C536A0F

Q36851454-2A59643D-997C-4C15-90F6-23866F26DFA1

P304

Q36851454-DDA559DB-14E8-44B5-B14A-B25DF82A0908

P31

Q36851454-CAF6D58E-ABBA-4E95-981E-FC3BAC2774EB

P356

Q36851454-FA74D833-F12D-4021-8EE9-BCB95EF1CE83

P407

Q36851454-969CDEDA-593C-45DB-A59C-33555223A66A

P433

Q36851454-1FE0A023-96C6-471C-816F-05948402674D

P478

Q36851454-041102D8-7F77-4E25-B735-13602D926C55

P50

Q36851454-2287258F-81A1-4DE8-B20C-7BE68FCA5F51

Q36851454-49E85D05-B4EC-4A7E-812D-BECB78671CC2

Q36851454-59D9F088-3D98-4202-A90D-2C922FDD6AA4

Q36851454-9466D389-CFFA-4178-98C6-F7F69A126C6F

Q36851454-C22B8527-867E-4DFF-BEF2-D5A390EEE7C5

P577

Q36851454-119B1E5F-2600-4A1B-9F59-955495557E78

P698

Q36851454-88A164FB-010C-4F50-AEBB-2BE7CEFF5590

P921

Q36851454-48F7E474-5896-4E25-B00B-7C93F2FF483A

P932

Q36851454-EAB1BF54-9374-4741-8431-D0095E1B74A3

P356

J.AMJMED.2013.01.004

P1433

The American Journal of Medicine

P1476

Angiotensin-converting enzyme ...... d preserved ejection fraction.

@en

P2093

Dalane W Kitzman

http://www.w3.org/2001/XMLSchema#string

Inmaculada B Aban

http://www.w3.org/2001/XMLSchema#string

Kanan Patel

http://www.w3.org/2001/XMLSchema#string

Meredith L Kilgore

http://www.w3.org/2001/XMLSchema#string

O James Ekundayo

http://www.w3.org/2001/XMLSchema#string

Thomas E Love

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.

Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.

Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.

Calculating the number needed to treat for trials where the outcome is time to an event

A structural approach to selection bias.

Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.

A propensity-matched study of the association of peripheral arterial disease with cardiovascular outcomes in community-dwelling older adults.

Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data.

P304

401-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJMED.2013.01.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

Gregg C. Fonarow

Richard M Allman

Mihai Gheorghiade

P577

2013-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23510948

http://www.w3.org/2001/XMLSchema#string

P921

P932

3656660

http://www.w3.org/2001/XMLSchema#string